C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

16 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

09 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 

08 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

24 Feb 2022 07:00:03 By Nasdaq GlobeNewswire

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Added to NASDAQ Biotechnology Index

17 Dec 2021 08:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

10 Nov 2021 16:01:01 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

11 Aug 2021 16:02:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma

11 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

21 Jun 2021 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

21 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Pricing of Public Offering

16 Jun 2021 19:51:25 By Nasdaq GlobeNewswire

C4 Therapeutics Launches Proposed Public Offering

14 Jun 2021 16:12:23 By Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies

14 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

07 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies

26 May 2021 07:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Lauren White as Chief Financial Officer

20 May 2021 16:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

13 May 2021 16:01:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Present at Upcoming Investor Conferences

12 May 2021 07:00:00 By Nasdaq GlobeNewswire